Changes in Beneficial Ownership · 4
Immatics N.V.
IMTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-26
- Issuer
- Immatics N.V.
- Issuer CIK
- 0001809196
- Trading symbol
- IMTX
Reporting owner 1
- Name
- PERCEPTIVE ADVISORS LLC
- Reporting owner CIK
- 0001224962
- Relationship
- Director
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY, 10003
Reporting owner 2
- Name
- EDELMAN JOSEPH
- Reporting owner CIK
- 0001164426
- Relationship
- Director
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY, 10003
Reporting owner 3
- Name
- PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
- Reporting owner CIK
- 0001249675
- Relationship
- Director
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY, 10003
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | 2026-08-26 | P · Form 4 | 863,060 | A | 8.69 | 11,246,516 | I | See Footnote[F1] |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.↩ 1
Signature 1
- Signed
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman
- Date
- 2026-08-27
Signature 2
- Signed
- /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
- Date
- 2026-08-27
Signature 3
- Signed
- /s/ Joseph Edelman
- Date
- 2026-08-27
Company context
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.